Jeong Keun Lee1, Kyung-Wook Kim2, Jin-Young Choi3, Seong-Yong Moon4, Su-Gwan Kim4, Chul-Hwan Kim2, Hyeon-Min Kim5, Yong-Dae Kwon6, Yong-Deok Kim7, Dong-Keun Lee8, Seung-Ki Min9, In-Sook Park10, Young-Wook Park11, Min-Suk Kook12, Hong-Ju Park12, Jin-A Baek13, Jun-Woo Park14, Tae-Geon Kwon15. 1. Board of Bone Bank, Ajou University, Suwon, Korea. 2. Board of Bone Bank, Dankook University, Cheonan, Korea. 3. Board of Bone Bank, Seoul National University, Seoul, Korea. 4. Board of Bone Bank, Chosun University, Gwangju, Korea. 5. Board of Bone Bank, Gachon University Gil Medical Center, Incheon, Korea. 6. Board of Bone Bank, Kyung Hee University, Seoul, Korea. 7. Board of Bone Bank, Pusan National University, Yangsan, Korea. 8. Board of Bone Bank, Daejeon Sun Hospital, Daejeon, Korea. 9. Board of Bone Bank, Wonkwang University, Iksan, Korea. 10. Board of Bone Bank, Catholic University of Daegu, Daegu, Korea. 11. Board of Bone Bank, Gangneung-Wonju National University, Gangneung, Korea. 12. Board of Bone Bank, Chonnam National University, Gwangju, Korea. 13. Board of Bone Bank, Chonbuk National University, Jeonju, Korea. 14. Board of Bone Bank, Hallym University Kangdong Sacred Heart Hospital, Seoul, Korea. 15. Board of Bone Bank, Kyungpook National University, Daegu, Korea.
Abstract
OBJECTIVES: Bisphosphonates (BP) are widely used in medicine for inhibiting bone resorption; however bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a major side effect of BP. To date, there have been no specific reports on the incidence of BRONJ among Koreans. This study investigated the preliminary results from a nationwide survey of BRONJ in the Departments of Oral and Maxillofacial Surgery (OMFS) at individual training hospitals. MATERIALS AND METHODS: A total of 15 OMFS departments (10 from dental schools, 4 from medical schools, and 1 from a dental hospital) participated in a multi-centric survey. This study assessed every BRONJ case diagnosed between January 2010 and December 2010. The patient age and BP type were evaluated. RESULTS: A total of 254 BRONJ cases were collected. The majority of BRONJ cases were associated with oral BP therapy, while 21.8% of the cases were associated with intravenous administration. Alendronate was the drug most frequently related to BRONJ (59.2% of cases), followed by risedronate (14.3%) and zolendronate (17.0%). The average age of BRONJ patients was 70.0±10.1 years, with a range of 38-88 years of age. With the number of BP patients in Korea reported to be around 600,000 in 2008, the estimated incidence of BRONJ is at least 0.04% or 1 per 2,300 BP patients. CONCLUSION: The results suggest that the estimated incidence of BRONJ in Korea is higher than the incidence of other countries. Future prospective studies should be carried out to investigate the exact epidemiological characteristics of BRONJ in Korea.
OBJECTIVES:Bisphosphonates (BP) are widely used in medicine for inhibiting bone resorption; however bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a major side effect of BP. To date, there have been no specific reports on the incidence of BRONJ among Koreans. This study investigated the preliminary results from a nationwide survey of BRONJ in the Departments of Oral and Maxillofacial Surgery (OMFS) at individual training hospitals. MATERIALS AND METHODS: A total of 15 OMFS departments (10 from dental schools, 4 from medical schools, and 1 from a dental hospital) participated in a multi-centric survey. This study assessed every BRONJ case diagnosed between January 2010 and December 2010. The patient age and BP type were evaluated. RESULTS: A total of 254 BRONJ cases were collected. The majority of BRONJ cases were associated with oral BP therapy, while 21.8% of the cases were associated with intravenous administration. Alendronate was the drug most frequently related to BRONJ (59.2% of cases), followed by risedronate (14.3%) and zolendronate (17.0%). The average age of BRONJpatients was 70.0±10.1 years, with a range of 38-88 years of age. With the number of BPpatients in Korea reported to be around 600,000 in 2008, the estimated incidence of BRONJ is at least 0.04% or 1 per 2,300 BPpatients. CONCLUSION: The results suggest that the estimated incidence of BRONJ in Korea is higher than the incidence of other countries. Future prospective studies should be carried out to investigate the exact epidemiological characteristics of BRONJ in Korea.
Entities:
Keywords:
Bisphosphonate; Data collection; Jaw; Osteonecrosis
Authors: Salvatore L Ruggiero; Thomas B Dodson; Leon A Assael; Regina Landesberg; Robert E Marx; Bhoomi Mehrotra Journal: J Oral Maxillofac Surg Date: 2009-05 Impact factor: 1.895
Authors: Paolo Vescovi; Giuseppina Campisi; Vittorio Fusco; Giovanni Mergoni; Maddalena Manfredi; Elisabetta Merigo; Luigi Solazzo; Mario Gabriele; Giovanni M Gaeta; Gianfranco Favia; Franco Peluso; Giuseppe Colella Journal: Oral Oncol Date: 2011-02-02 Impact factor: 5.337
Authors: S A Khan; J A Kanis; S Vasikaran; W F Kline; B K Matuszewski; E V McCloskey; M N Beneton; B J Gertz; D G Sciberras; S D Holland; J Orgee; G M Coombes; S R Rogers; A G Porras Journal: J Bone Miner Res Date: 1997-10 Impact factor: 6.741
Authors: Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane Journal: J Bone Miner Res Date: 2007-10 Impact factor: 6.741